L-Tyrosine Supplementation in Patients With Fibromyalgia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01219049|
Recruitment Status : Terminated (Due to FDA comments, changes required unavailable resources. There are no results for this study.)
First Posted : October 13, 2010
Last Update Posted : April 11, 2017
|Condition or disease||Intervention/treatment||Phase|
|Fibromyalgia||Drug: Tyrosine Drug: Placebo||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||15 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||L-Tyrosine Supplementation in Patients With Fibromyalgia|
|Study Start Date :||January 2010|
|Actual Primary Completion Date :||January 2011|
|Actual Study Completion Date :||January 2011|
Experimental: Tyrosine 1000 mg / day
Patients receive 1000 mg tyrosine per day.
1000 mg / day
Experimental: Tyrosine 2000 mg / day
Patients receive 2000 mg tyrosine per day.
2000 mg / day
Placebo Comparator: Placebo
Patients receive placebo daily.
- Pain Score [ Time Frame: daily for 21 days ]
- FIQ Score [ Time Frame: Day 1 ]
- FIQ Score [ Time Frame: Day 21 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01219049
|United States, New York|
|Mount Sinai School of Medicine|
|New York, New York, United States, 10029|
|Principal Investigator:||Michael A Mazzeffi, MD, MPH||Icahn School of Medicine at Mount Sinai|